Cannabis legalization in the UK and the Cannabis Industry Council (CIC)

Nov 23, 2021 | Blogs, Cannabis, Food / Beverage | 0 comments

Read time: 4 minutes

Introduction to UK cannabis legalization

The legalization of cannabis in the UK is a hot topic as public demand continues to rise. While the UK legalized medical cannabis in late 2018, doctors have so far been reluctant to issue prescriptions. There could be change on the horizon, however. Sadiq Khan, Mayor of London, plans to launch a review that looks at decriminalizing cannabis, which could mean an expansion opportunity and a positive outlook for global cannabis stocks. During his 2021 reelection campaign, Khan said he would establish a London Drug Commission to consider the effectiveness of UK drug laws, with a focus on cannabis. Although Khan is keen to make cannabis as available as other prescription medicines, so far the rest of the UK government isn’t on board. However, with 47% of Brits in favor of legalizing and regulating cannabis, could change be coming to UK cannabis laws in the near future?

Patient access to medicinal marijuana

In early 2020, the UK government announced a change to import restrictions that aims to help ensure prescriptions for cannabis-based products for medicinal use are not delayed or interrupted. Detailed in the change is the ability of licensed wholesalers to import larger quantities of cannabis-based products and to hold supplies for future use by patients with prescriptions. In addition, the government will continue to engage with medical associations and patients to build evidence, using trials in the UK, to accelerate the understanding of how medicinal cannabis can benefit patients.

Although the legalization of cannabis seems to be a much-discussed topic when it comes to UK government regulations, there is still a long way to go. Since the introduction of the 2018 law to enable the legal prescription of cannabis-based medicinal products (CBMPs), there has been only around 400 private prescriptions and 2 NHS prescriptions.

To help bridge this gap, there are groups working on accelerating the integration of CBMPs into UK healthcare. Let’s take a look at the first representative cannabis body dedicated to advancing the UK cannabis sector: the Cannabis Industry Council (CIC).

What is the CIC?

Launched in 2021, the CIC is a collective of organizations, business and working groups that have united with the hope of strengthening ties between the cannabis industry and the UK public sector and reducing the governmental red tape that currently restricts industry growth. The CIC comprises 6 subgroups—including Quality Standards and Environmental & Social Responsibility—and membership invitations have been extended to representatives from the Home Office, the Department of Health and NHS England. So far, the CIC has 60 members, with the hope of reaching 100 and then pushing on from there. Prof. Mike Barnes, Chairman of the Medical Cannabis Clinicians Society, is a driver of the CIC and believes “we need a voice to represent the industry as a whole.” He states 3 main aims of the group:

• “Be the voice for the industry as whole, so if the government has any particular issue I would like to see them come to us first, as we will have the expertise to talk to them across all of the sectors.”

• “We need to counteract the negatives that come in the press in relation to cannabis, so the media, marketing and PR-side is really important, too.”

• “Push for prescriptions on the NHS to make it widely available to all those who need it.”

The most recent election to the group is Elisabetta Faenza, CEO of LeafCann, which is a group that focuses on building a robust and agile medicinal cannabis supply chain. Faenza holds the position of Chair of the Standards Group for the CIC. As the new group is still in its early stages, it will be interesting to see the impact it might have on the cannabis industry in the UK.

Full-scale decriminalization and recreational cannabis use in the UK might still be a ways off, but with nearly half of Brits in favor of legalization1, we might see cannabis use in the UK rise in the (near) future. This could mean increased demand and need for testing to adhere to limits and, even more important, protect customers and consumers. With support from SCIEX instrumentation, you can help improve detection confidence, tighten precision and simplify workflows in your cannabis analysis to meet the demands and needs of the changing market.

Don’t forget to leave a comment, share your thoughts and predictions and stay tuned for more blogs to come in the series.

References

1. Farley, A. Is London’s mayor teeing up a UK cannabis revolution? Value the Markets, April 12, 2021. https://www.valuethemarkets.com/2021/04/12/london-mayor-teeing-revolution-cannabis-stocks/
2. Somerset, S.B. Cannabis Patients In The United Kingdom Are Granted Faster Access To Their Medicine. Forbes, March 3, 2020. https://www.forbes.com/sites/sarabrittanysomerset/2020/03/03/cannabis-patients-in-the-united-kingdom-are-granted-faster-access-to-their-medicine/
3. Health Europa. New council body launched to demand robust UK cannabis industry. Medical Cannabis Network, June 7, 2021. https://www.healtheuropa.eu/new-council-body-launched-to-demand-robust-uk-cannabis-industry/108710/
4. McCusker, P. New Cannabis Industry Council Aims To Create A Single Unified Cannabis Voice For The UK. BusinessCann, April 16, 2021. https://businesscann.com/new-cannabis-industry-council-aims-to-create-a-single-unified-cannabis-voice-for-the-uk/

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

Senior Applications Scientist, SCIEX. Diana Tran specializes in LC-MS/MS method development as an applications scientist at SCIEX. For the past 4 years, she has been actively involved in cannabis testing analysis and has had a hand in almost every cannabis method developed at SCIEX since then. Diana has been field tested in testing labs across the US, making connections in cannabis testing labs and acting as a resource for analytical chemists. She is always looking for new cannabuds—feel free to reach out and start a conversation.

Tags


0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial